Royal Philips, a global leader in health technology, has unveiled IntraSight Plus, its next-generation interventional guidance platform, now cleared for clinical use in the U.S. and Europe with relevant approvals. 

 

The redesigned system consolidates diagnostic and treatment-planning tools into a single, intuitive interface, streamlining access to key interventional functions and enabling clinicians to diagnose, plan, guide, and verify procedures—all on one screen.

 

“IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision.

 

Traditionally, interventional cardiologists have relied primarily on angiography for percutaneous coronary interventions (PCI), with intravascular ultrasound and physiological assessments often handled separately. IntraSight Plus addresses these inefficiencies, offering a fully integrated system that can cut system operation time by up to 47% and provide complete bedside control.

 

“As more advanced technology is integrated into the cath lab, the need for connectivity between the imaging tools is more important than ever before,” said Stacy Beske, Business Leader Image-Guided Therapy Devices at Philips. “IntraSight Plus was built using feedback from our customers and represents a fundamental shift in interventional cardiology – a future driven by integrated intelligence that lets physicians focus on the decision-making that only they can do.”

 

The platform’s clinical debut took place Thursday, March 19, 2026, when Dr. Jan-Malte Sinning performed the first patient procedure at Cellitinnen-Krankenhaus St. Vinzenz in Köln, Germany. The hospital recently upgraded its cath lab with Philips’ Azurion interventional suites, now enhanced by the addition of IntraSight Plus.

 

“Modern PCI is becoming increasingly complex,” said Dr. Sinning. “Intravascular imaging combined with physiology provides the level of detail we need for contemporary PCI. What stands out with IntraSight Plus is that the platform is clearly designed around how we actually work in the cath lab – combining physiology, imaging and decision-making support in a way that fits naturally into the clinical workflow.”

 

The first patient treated had an acute ST-elevation myocardial infarction (STEMI) of the left anterior descending (LAD) artery and underlying complex three-vessel disease. Using the integrated Azurion and IntraSight Plus platform, Dr. Sinning completed full revascularization prior to discharge.

 

The system’s tri-registration of angiography, physiological assessment, and intravascular imaging enabled a smooth, intuitive workflow, allowing the team to focus on hemodynamically relevant lesions and ensure optimal stent deployment for improved patient outcomes.